Celularity CEO supports CMS withdrawal of skin substitute LCDs impacting Biovance® products for Medicare coverage.
Celularity's Biovance® and Biovance 3L products were approved for Medicare coverage before the LCDs were removed. The CEO, Dr. Robert J. Hariri, expressed approval of the recent actions led by CMS Administrator Dr. Mehmet Oz.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments